614 related articles for article (PubMed ID: 30430276)
1. Review of Immune Therapies Targeting Ovarian Cancer.
Fan CA; Reader J; Roque DM
Curr Treat Options Oncol; 2018 Nov; 19(12):74. PubMed ID: 30430276
[TBL] [Abstract][Full Text] [Related]
2. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
3. [Specific immunotherapies in the treatment of cancers].
Denis H; Davoine C; Bermudez E; Grosjean G; Schwager M; Ifrah N; Dahan M; Negellen S
Bull Cancer; 2019 Jan; 106(1):37-47. PubMed ID: 30638899
[TBL] [Abstract][Full Text] [Related]
4. [Current advances in immunotherapy in ovarian cancer].
Le Saux O; Dubois B; Stern MH; Terme M; Tartour E; Classe JM; Chopin N; Trédan O; Caux C; Ray-Coquard I
Bull Cancer; 2020 Apr; 107(4):465-473. PubMed ID: 32089245
[TBL] [Abstract][Full Text] [Related]
5. Vasculitis associated with immune checkpoint inhibitors-a systematic review.
Daxini A; Cronin K; Sreih AG
Clin Rheumatol; 2018 Sep; 37(9):2579-2584. PubMed ID: 29923081
[TBL] [Abstract][Full Text] [Related]
6. A decade of immune-checkpoint inhibitors in cancer therapy.
Robert C
Nat Commun; 2020 Jul; 11(1):3801. PubMed ID: 32732879
[TBL] [Abstract][Full Text] [Related]
7. The Role of PD-1 Checkpoint Inhibition in Gynecologic Malignancies.
Garcia C; Ring KL
Curr Treat Options Oncol; 2018 Nov; 19(12):70. PubMed ID: 30397772
[TBL] [Abstract][Full Text] [Related]
8. [Immunotherapy of Renal Cell Carcinoma].
Poprach A; Lakomý R; Büchler T
Klin Onkol; 2017; 30(Supplementum3):55-61. PubMed ID: 29239194
[TBL] [Abstract][Full Text] [Related]
9. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
[TBL] [Abstract][Full Text] [Related]
10. New Approaches for Immune Directed Treatment for Ovarian Cancer.
Hardwick N; Frankel PH; Cristea M
Curr Treat Options Oncol; 2016 Mar; 17(3):14. PubMed ID: 26942589
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in the clinical development of immune checkpoint blockade therapy.
Ghahremanloo A; Soltani A; Modaresi SMS; Hashemy SI
Cell Oncol (Dordr); 2019 Oct; 42(5):609-626. PubMed ID: 31201647
[TBL] [Abstract][Full Text] [Related]
12. New Clinical Approaches and Emerging Evidence on Immune-Checkpoint Inhibitors as Anti-Cancer Therapeutics: CTLA-4 and PD-1 Pathways and Beyond.
Christodoulou MI; Zaravinos A
Crit Rev Immunol; 2019; 39(5):379-408. PubMed ID: 32422018
[TBL] [Abstract][Full Text] [Related]
13. Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology.
Lee HT; Lee SH; Heo YS
Molecules; 2019 Mar; 24(6):. PubMed ID: 30917623
[TBL] [Abstract][Full Text] [Related]
14. Targeting the tumor microenvironment and T cell metabolism for effective cancer immunotherapy.
Hope HC; Salmond RJ
Eur J Immunol; 2019 Aug; 49(8):1147-1152. PubMed ID: 31270810
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
Hargadon KM; Johnson CE; Williams CJ
Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy in genitourinary malignancies.
Mehta K; Patel K; Parikh RA
J Hematol Oncol; 2017 Apr; 10(1):95. PubMed ID: 28434403
[TBL] [Abstract][Full Text] [Related]
17. Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors.
Gay F; D'Agostino M; Giaccone L; Genuardi M; Festuccia M; Boccadoro M; Bruno B
Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):471-478. PubMed ID: 28689001
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitors in the management of malignancies in transplant recipients.
Regalla DKR; Williams GR; Paluri RK
Postgrad Med J; 2018 Dec; 94(1118):704-708. PubMed ID: 30425139
[TBL] [Abstract][Full Text] [Related]
19. Use of Immune Checkpoint Inhibitors in Mesothelioma.
Forde PM; Scherpereel A; Tsao AS
Curr Treat Options Oncol; 2019 Feb; 20(2):18. PubMed ID: 30762130
[TBL] [Abstract][Full Text] [Related]
20. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]